文献速递产科母胎医学

双胎妊娠早期阴道孕酮与安慰剂预防自发性早产的随机双盲试验

Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial.
PubMed 文献 · Am J Obstet Gynecol · 2020-06-26

该随机双盲试验在6个国家22家医院纳入1194例双胎孕妇,比较孕11至14周起每日阴道孕酮600 mg与安慰剂至孕34周对24+0至33+6周自发性早产的预防效果。结果显示孕酮组与安慰剂组自发性早产率无显著差异(10.4% vs 8.2%,校正OR 1.35,95%CI 0.88-2.05,P=.17)。事后分析提示孕酮可能对宫颈长度<30 mm者有益、对≥30 mm者可能增加风险。

要点

  • 双胎孕妇每日阴道孕酮600 mg未能降低24+0至33+6周自发性早产发生率。
  • 孕酮组自发性早产10.4%(56/541),安慰剂组8.2%(44/538),校正OR 1.35(95%CI 0.88-2.05,P=.17)。
  • 事后分析提示宫颈长度<30 mm者用孕酮可能获益(OR 0.56),≥30 mm者可能受害(OR 1.61)。

核心结论

  • 在双胎妊娠妇女中,普遍使用阴道孕酮未能降低24+0至33+6周自发性早产的发生率。
  • 事后时间-事件分析提示,孕酮可能降低宫颈长度<30 mm妇女32周前自发性早产的风险,并可能增加宫颈长度≥30 mm者的风险。

研究设计与样本

  • 随机、安慰剂对照、双盲试验,在英国、西班牙、保加利亚、意大利、比利时和法国的22家医院进行。
  • 2017年5月至2019年4月共招募1194名妇女,21人撤回知情同意、4人失访,最终孕酮组582人、安慰剂组587人。
  • 按1:1比例随机分配接受孕酮或安慰剂,随机序列生成按参与中心分层。
  • 主要结局为24+0至33+6周妊娠间的自发性分娩,统计分析基于意向性治疗原则。
  • 采用逻辑回归分析校正参与中心、绒毛膜性、产次和受孕方式,并预设检验与绒毛膜性、产次、受孕方式、依从性和入组时宫颈长度的交互作用。

主要发现

  • 排除24周前分娩和34周前指征性分娩后,孕酮组24+0至33+6周自发性分娩发生率为10.4%(56/541),安慰剂组为8.2%(44/538),校正OR 1.35(95%CI 0.88-2.05,P=.17)。
  • 治疗效应与绒毛膜性(P=.28)、产次(P=.35)、受孕方式(P=.56)和依从性(P=.34)无交互作用证据;与宫颈长度存在弱交互作用证据(P=.08),提示宫颈长度≥30 mm者可能受害(OR 1.61,95%CI 1.01-2.59),宫颈长度<30 mm者可能获益(OR 0.56,95%CI 0.20-1.60)。
  • 两组在死产或新生儿死亡、新生儿并发症、新生儿治疗和胎儿生长不良方面无差异证据。
  • 孕酮组1.4%(8/582)妇女和1.9%(22/1164)胎儿经历至少1次严重不良事件;安慰剂组分别为1.2%(7/587)和3.2%(37/1174)(P=.80和P=.06)。
  • 事后时间-事件分析中,孕酮组随机化至31+6周妊娠间的流产或自发性早产较安慰剂组减少(HR 0.23,95%CI 0.08-0.69)。

关键数值与推荐

  • 孕酮用法:每日阴道孕酮600 mg,从孕11至14周至孕34周。
  • 主要结局:24+0至33+6周妊娠间的自发性分娩。
  • 宫颈长度≥30 mm者孕酮组OR 1.61(95%CI 1.01-2.59),宫颈长度<30 mm者OR 0.56(95%CI 0.20-1.60)。

临床怎么用

  • 双胎妊娠中普遍使用阴道孕酮未能降低24+0至33+6周自发性早产发生率,原文未据此给出推荐。
  • 作者在事后分析中提出,孕酮可能降低宫颈长度<30 mm妇女32周前自发性早产风险,并可能增加宫颈长度≥30 mm者的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In women with a singleton pregnancy and sonographic short cervix in midgestation, vaginal administration of progesterone reduces the risk of early preterm birth and improves neonatal outcomes without any demonstrable deleterious effects on childhood neurodevelopment. In women with twin pregnancies, the rate of spontaneous early preterm birth is 10 times higher than that in singletons, and in this respect, all twins are at an increased risk of preterm birth. However, 6 trials in unselected twin pregnancies reported that vaginal administration of progesterone from midgestation had no significant effect on the incidence of early preterm birth. Such apparent lack of effectiveness of progesterone in twins may be due to inadequate dosage or treatment that is started too late in pregnancy. OBJECTIVE: The early vaginal progesterone for the prevention of spontaneous preterm birth in twins, a randomized, placebo-controlled, double-blind trial, was designed to test the hypothesis that among women with twin pregnancies, vaginal progesterone at a dose of 600 mg per day from 11 to 14 until 34 weeks' gestation, as compared with placebo, would result in a significant reduction in the incidence of spontaneous preterm birth between 24+0 and 33+6 weeks. STUDY DESIGN: The trial was conducted at 22 hospitals in England, Spain, Bulgaria, Italy, Belgium, and France. Women were randomly assigned in a 1:1 ratio to receive either progesterone or placebo, and in the random-sequence generation, there was stratification according to the participating center. The primary outcome was spontaneous birth between 24+0 and 33+6 weeks' gestation. Statistical analyses were performed on an intention-to-treat basis. Logistic regression analysis was used to determine the significance of difference in the incidence of spontaneous birth between 24+0 and 33+6 weeks' gestation between the progesterone and placebo groups, adjusting for the effect of participating center, chorionicity, parity, and method of conception. Prespecified tests of treatment interaction effects with chorionicity, parity, method of conception, compliance, and cervical length at recruitment were performed. A post hoc analysis using mixed-effects Cox regression was used for further exploration of the effect of progesterone on preterm birth. RESULTS: We recruited 1194 women between May 2017 and April 2019; 21 withdrew consent and 4 were lost to follow-up, which left 582 in the progesterone group and 587 in the placebo group. Adherence was good, with reported intake of ≥80% of the required number of capsules in 81.4% of the participants. After excluding births before 24 weeks and indicated deliveries before 34 weeks, spontaneous birth between 24+0 and 33+6 weeks occurred in 10.4% (56/541) of participants in the progesterone group and in 8.2% (44/538) in the placebo group (odds ratio in the progesterone group, adjusting for the effect of participating center, chorionicity, parity, and method of conception, 1.35; 95% confidence interval, 0.88-2.05; P=.17). There was no evidence of interaction between the effects of treatment and chorionicity (P=.28), parity (P=.35), method of conception (P=.56), and adherence (P=.34); however, there was weak evidence of an interaction with cervical length (P=.08) suggestive of harm to those with a cervical length of ≥30 mm (odds ratio, 1.61; 95% confidence interval, 1.01-2.59) and potential benefit for those with a cervical length of <30 mm (odds ratio, 0.56; 95% confidence interval, 0.20-1.60). There was no evidence of difference between the 2 treatment groups for stillbirth or neonatal death, neonatal complications, neonatal therapy, and poor fetal growth. In the progesterone group, 1.4% (8/582) of women and 1.9% (22/1164) of fetuses experienced at least 1 serious adverse event; the respective numbers for the placebo group were 1.2% (7/587) and 3.2% (37/1174) (P=.80 and P=.06, respectively). In the post hoc time-to-event analysis, miscarriage or spontaneous preterm birth between randomization and 31+6 weeks' gestation was reduced in the progesterone group relative to the placebo group (hazard ratio, 0.23; 95% confidence interval, 0.08-0.69). CONCLUSION: In women with twin pregnancies, universal treatment with vaginal progesterone did not reduce the incidence of spontaneous birth between 24+0 and 33+6 weeks' gestation. Post hoc time-to-event analysis led to the suggestion that progesterone may reduce the risk of spontaneous birth before 32 weeks' gestation in women with a cervical length of <30 mm, and it may increase the risk for those with a cervical length of ≥30 mm.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rehal A, Benkő Z, De Paco Matallana C, et al. Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. Am J Obstet Gynecol. 2020. PMID: 32598909. doi:10.1016/j.ajog.2020.06.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。